The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Clinical Implication of Hot Spot BRAF Mutation, V599E, in Papillary Thyroid Cancers
Abstract
Activating mutations in the BRAF kinase gene have recently been reported in human cancers. The aim of the present study was to determine the frequency of BRAF mutations in thyroid cancer and their correlation with clinicopathological parameters. We analyzed exons 11 and 15 of BRAF gene in six human thyroid cancer cell lines and 207 paraffin-embedded thyroid tumor tissues. A missense mutation was found at T1796A (V599E) in exon 15 in four of the six cell lines and 51 of 207 thyroid tumors (24.6%; 0 of 20 follicular adenoma, 0 of 11 follicular carcinoma, 49 of 170 papillary carcinomas, and 2 of 6 undifferentiated carcinomas). Activation of MAPK kinase-MAPK pathway was observed in cell lines harboring BRAF mutation. BRAF mutation-associated enhanced cell growth was suppressed by MAPK kinase inhibitor, U0126. Examination of 126 patients with papillary thyroid cancer showed that BRAF mutation correlated significantly with distant metastasis (P = 0.033) and clinical stage (P = 0.049). Our results indicate that activating mutation of BRAF gene could be a potentially useful marker of prognosis of patients with advanced thyroid cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
A synthetic inhibitor of the mitogen-activated protein kinase cascade.
Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., & Saltiel, A. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7686 · Cited by 2,679
International Histological Classification of Tumours
Weller, R. (1981) · Journal of Clinical Pathology · doi:10.1136/jcp.34.6.692-d · Cited by 2,042
High frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730
HAY, I. D., Bergstralh, E. J., Goellner, J. R., Ebersold, J. R., & Grant, C. S. (1993) · PubMed · Cited by 1,223
BRAF and RAS mutations in human lung cancer and melanoma.
Brose, M. S., Volpe, P., Feldman, M. D., Kumar, M. S., Rishi, I., Gerrero, R. M., Einhorn, E., Herlyn, M., Minna, J. D., Nicholson, A. G., et al. (2002) · PubMed · Cited by 1,048
Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
Sebolt-Leopold, J. S., Dudley, D. T., Herrera, R., Becelaere, K. V., Wiland, A., Gowan, R. C., Tecle, H., Barrett, S. D., Bridges, A., Przybranowski, S., et al. (1999) · Nature Medicine · doi:10.1038/10533 · Cited by 970
High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.
Fagin, J. A., Matsuo, K., Karmakar, A., Chen, D. L., Tang, S. H., & Koeffler, H. P. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116168 · Cited by 649
Carlomagno, F., Vitagliano, D., Guida, T., Ciardiello, F., Tortora, G., Vecchio, G., Ryan, A. J., Fontanini, G., Fusco, A., & Santoro, M. M. (2002) · PubMed · Cited by 569
RET/PTC Rearrangement in Thyroid Tumors
Nikiforov, Y. E. (2002) · Endocrine Pathology · doi:10.1385/ep:13:1:03 · Cited by 489
Yuen, S. T., Davies, H. R., Chan, T. L., Ho, J. W. C., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Tsui, W. W., Chan, A. S. Y., et al. (2002) · PubMed · Cited by 404
Cancer incidence and mortality, 1973-1995: A report card for the U.�S.
Wingo, P. A., Ries, L. A. �., Rosenberg, H. M., Miller, D. S., & Edwards, B. K. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980315)82:6<1197::aid-cncr26>3.0.co;2-0 · Cited by 392
Missense mutations of the BRAF gene in human lung adenocarcinoma.
Naoki, K., Chen, T. H., Richards, W. G., Sugarbaker, D. J., & Meyerson, M. M. (2002) · PubMed · Cited by 287
Presence of mutations in all three ras genes in human thyroid tumors.
Suarez, H. G., Ja, D. V., Severino, M. E., Caillou, B., Schlumberger, M. J., Tubiana, M., Parmentier, C., & Monier, R. (1990) · PubMed · Cited by 262
Activated ras oncogenes in human thyroid cancers.
Lemoine, N. R., Mayall, E. S., Wyllie, F. S., Farr, C. J., Hughes, D., Padua, R. A., Thurston, V., Williams, E. D., & Wynford‐Thomas, D. (1988) · PubMed · Cited by 233
Molecular Basis of Thyroid Cancer*
FARID, N. R., SHI, Y., & ZOU, M. (1994) · Endocrine Reviews · doi:10.1210/edrv-15-2-202 · Cited by 226
Signaling pathways in Ras-mediated tumorigenicity and metastasis
Webb, C. P., Van Aelst, L., Wigler, M. H., & Vande Woude, G. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8773 · Cited by 192
Ras Oncogene Mutations in Benign and Malignant Thyroid Neoplasms
KARGA, H., LEE, J.-K., VICKERY, A. L., THOR, A., GAZ, R. D., & JAMESON, J. L. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-4-832 · Cited by 175
A genome-based strategy uncovers frequent BRAF mutations in melanoma
Pollock, P. M., & Meltzer, P. S. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00089-2 · Cited by 160
H-Ras Protooncogene Mutations in Human Thyroid Neoplasms*
Namba, H., Gutman, R. A., MATSUO, K., Alvarez, A., & Fagin, J. A. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-71-1-223 · Cited by 109
Self-citationKurebayashi, J., Tanaka, K., Otsuki, T., Moriya, T., Kunisue, H., Uno, M., & Sonoo, H. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.8.6732 · Cited by 109
Conditional Apoptosis Induced by Oncogenic Ras in Thyroid Cells
Shirokawa, J. M., Elisei, R., Knauf, J. A., Hara, T., Wang, J., Saavedra, H. I., & Fagin, J. A. (2000) · Molecular Endocrinology · doi:10.1210/mend.14.11.0559 · Cited by 62
Cited by
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
Cooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Pacini, F., Schlumberger, M., et al. (2009) · Thyroid · doi:10.1089/thy.2009.0110 · Cited by 6,707
ERK/MAPK signalling pathway and tumorigenesis (Review)
Guo, Y., Pan, W., Liu, S., Shen, Z., Xu, Y., & Hu, L. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8454 · Cited by 1,475
Molecular pathogenesis and mechanisms of thyroid cancer
Xing, M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3431 · Cited by 1,426
BRAF mutation in thyroid cancer
Xing, M. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.0978 · Cited by 1,300
Metadata
- Authors
- Namba, H., Nakashima, M., Hayashi, T., Hayashida, N., Maeda, S., Rogounovitch, T. I., Ohtsuru, A., Saenko, V. A., Kanematsu, T., & Yamashita, S.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2003-09
- Volume
- 88
- Issue
- 9
- Pages
- 4393-4397
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2098999691
- Cited by
- 533
- References
- 22
- FWCI
- 21.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.